Total Payments
$169,269
2024 Payments
$123,892
Companies
26
Transactions
221
Medicare Patients
324
Medicare Billing
$25,423
Payment Breakdown by Category
Research$152,403 (90.0%)
Other$9,300 (5.5%)
Food & Beverage$4,794 (2.8%)
Travel$1,413 (0.8%)
Consulting$1,350 (0.8%)
Education$8.65 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $152,403 | 16 | 90.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,300 | 8 | 5.5% |
| Food and Beverage | $4,794 | 185 | 2.8% |
| Travel and Lodging | $1,413 | 9 | 0.8% |
| Consulting Fee | $1,350 | 1 | 0.8% |
| Education | $8.65 | 2 | 0.0% |
Payments by Type
Research
$152,403
16 transactions
General
$16,866
205 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $150,953 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $10,098 | 36 | $0 (2022) |
| JAZZ PHARMACEUTICALS INC. | $1,802 | 47 | $0 (2019) |
| Harmony Biosciences LLC | $1,484 | 2 | $0 (2020) |
| Lexicon Pharmaceuticals, Inc. | $1,451 | 3 | $0 (2024) |
| Eisai Inc. | $1,273 | 10 | $0 (2017) |
| GlaxoSmithKline, LLC. | $607.94 | 43 | $0 (2023) |
| Mallinckrodt LLC | $250.33 | 2 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $215.35 | 9 | $0 (2023) |
| Mylan Specialty L.P. | $159.13 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $123,892 | 9 | Eli Lilly and Company ($122,319) |
| 2023 | $10,717 | 8 | Eli Lilly and Company ($10,651) |
| 2022 | $18,029 | 5 | Eli Lilly and Company ($17,982) |
| 2021 | $39.82 | 2 | Insmed, Inc. ($23.89) |
| 2020 | $2,876 | 5 | Harmony Biosciences LLC ($1,484) |
| 2019 | $810.84 | 22 | JAZZ PHARMACEUTICALS INC. ($470.25) |
| 2018 | $9,249 | 90 | AstraZeneca Pharmaceuticals LP ($7,701) |
| 2017 | $3,655 | 80 | Eisai Inc. ($1,273) |
All Payment Transactions
221 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | Eli Lilly and Company | — | — | In-kind items and services | $95.60 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 10/25/2024 | Eli Lilly and Company | — | — | In-kind items and services | $34.77 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $60,449.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $59,167.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,573.00 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 03/06/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Obesity | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $983.31 | Research |
| Study: LX9211 | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $248.02 | Research |
| Study: LX9211 | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $219.25 | Research |
| Study: LX9211 | ||||||
| 08/23/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.49 | General |
| 06/15/2023 | Eli Lilly and Company | — | — | In-kind items and services | $5,401.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | ||||||
| 06/11/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 04/27/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: IMMUNOLOGY | ||||||
| 02/01/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2,293.38 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,551.93 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $870.04 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | ||||||
| 01/03/2023 | Vapotherm Inc | VAPOTHERM (Device) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: RESPIRATORY | ||||||
| 08/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,544.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | ||||||
| 07/11/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,416.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 06/30/2022 | Eli Lilly and Company | — | — | In-kind items and services | $15,022.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 02/28/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Oncology | ||||||
| 02/09/2022 | Insmed, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 12/13/2021 | Olympus America Inc. | SPiN Thoracic Navigation System, 120V, 60Hz (Device) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Respiratory | ||||||
| 12/08/2021 | Insmed, Inc. | — | Food and Beverage | In-kind items and services | $23.89 | General |
| 08/26/2020 | Philips Electronics North America Corporation | (6299) DreamWear (Device) | Food and Beverage | Cash or cash equivalent | $28.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | Eli Lilly and Company | $65,850 | 2 |
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | Eli Lilly and Company | $59,798 | 3 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $17,315 | 2 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $2,968 | 2 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $2,608 | 2 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | Eli Lilly and Company | $2,414 | 2 |
| LX9211 | Lexicon Pharmaceuticals, Inc. | $1,451 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 7 | 324 | 382 | $54,816 | $25,423 |
Total Patients
324
Total Services
382
Medicare Billing
$25,423
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 141 | 160 | $23,769 | $10,467 | 44.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 63 | 82 | $16,146 | $8,417 | 52.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 33 | $3,514 | $1,936 | 55.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 24 | 26 | $2,614 | $1,221 | 46.7% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2020 | 26 | 27 | $3,041 | $1,185 | 39.0% |
| 94729 | Measurement of lung diffusing capacity | Office | 2020 | 26 | 27 | $2,854 | $1,104 | 38.7% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2020 | 26 | 27 | $2,878 | $1,094 | 38.0% |
About Dr. Daniel Lorch, M.D
Dr. Daniel Lorch, M.D is a Pulmonary Disease healthcare provider based in Brandon, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821033242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Lorch, M.D has received a total of $169,269 in payments from pharmaceutical and medical device companies, with $123,892 received in 2024. These payments were reported across 221 transactions from 26 companies. The most common payment nature is "" ($152,403).
As a Medicare-enrolled provider, Lorch has provided services to 324 Medicare beneficiaries, totaling 382 services with total Medicare billing of $25,423. Data is available for 1 year (2020–2020), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Sleep Medicine
- Location Brandon, FL
- Active Since 06/19/2006
- Last Updated 11/05/2013
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1821033242
Products in Payments
- BEVESPI AEROSPHERE (Drug) $9,808
- Wakix (Drug) $1,484
- Xyrem (Drug) $430.84
- XYREM (Drug) $385.59
- NUCALA (Biological) $270.38
- ACTHAR (Biological) $250.33
- TRELEGY ELLIPTA (Drug) $158.85
- FASENRA (Drug) $155.69
- WATCHMAN DEVICE (Device) $124.71
- ZEPBOUND (Drug) $121.84
- ANORO (Drug) $117.81
- SYMBICORT (Drug) $110.78
- Dymista (Drug) $93.38
- ORENITRAM (Drug) $88.43
- Adempas (Drug) $77.81
- TUDORZA PRESSAIR (Drug) $76.20
- Perforomist (Drug) $49.14
- OFEV (Drug) $48.01
- Esbriet (Biological) $47.19
- Kcentra (Biological) $43.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Brandon
Ivan Ackerman, M.d, M.D
Pulmonary Disease — Payments: $57,168
Pulmonary Disease $57,168
Dragos Zanchi, M.d, M.D
Pulmonary Disease — Payments: $45,595
Pulmonary Disease $45,595
Divyang Sorathia, M.d, M.D
Pulmonary Disease — Payments: $18,950
Pulmonary Disease $18,950
Dr. Arthur Graves, M.d, M.D
Pulmonary Disease — Payments: $4,613
Pulmonary Disease $4,613
Jonathan Axel, M.d, M.D
Pulmonary Disease — Payments: $1,644
Pulmonary Disease $1,644
Dr. Elizabeth Carpenter, Md, MD
Pulmonary Disease — Payments: $1,029
Pulmonary Disease $1,029